Understanding HCV Nonresponse and Identifying Candidates for Retreatment
Source: New Management Strategies for HCV Nonresponders and Relapsers


Mitchell L. Shiffman, MD, reviews the various types of virologic response in hepatitis C virus–infected patients treated with interferon and ribavirin-based regimens and explains how to identify patients who would be good candidates for retreatment if they fail to achieve sustained virologic response.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify standard definitions of response and nonresponse to hepatitis C virus therapy
  • Discuss factors associated with nonresponse to hepatitis C virus therapy
  • Report criteria that may help to identify nonresponders who are good candidates for retreatment
  • Summarize data from studies of different retreatment strategies
  • Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Topics covered include:

  • Introduction
  • Defining the Patterns of Virologic Response and Nonresponse
  • Rapid Virologic Response
  • Achieving Undetectable HCV RNA After Week 4 and Slow Virologic Response
  • Early Virologic Response and Nonresponse Virologic Patterns
  • Breakthrough and Relapse
  • Identifying Candidates for Retreatment: Null Response
  • Identifying Candidates for Retreatment: Partial Virologic Response
  • Identifying Candidates for Retreatment: Noncompliance, Medication Errors and Dose Reduction
  • Identifying Candidates for Retreatment: Failure to Recognize That Virologic Response Has Occurred
  • Identifying Candidates for Retreatment: Insufficient Treatment Duration
  • Conclusions
  • Summary of Clinical Implications


  • Mitchell L. Shiffman

Credit Information

  • Release Date:
    October 04, 2007
  • Expiration Date:
    October 03, 2008
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy

    Nancy Reau MD - 8/25/2015    12 comments / Last Comment: 10/29/2015
    A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015    5 comments / Last Comment: 11/9/2015
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • Post-EASL Update: Is It Time to Use Resistance Testing to Guide HCV Treatment Decisions?

    Jordan J. Feld MD, MPH - 7/28/2015    3 comments / Last Comment: 10/22/2015
    With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015    3 comments / Last Comment: 7/26/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • How I Expect Evolving Options for HCV Therapy Will Affect Posttransplant Management

    Paul Y. Kwo MD - 7/29/2015    1 comment / Last Comment: 10/10/2015
    Will we finally have options to prevent posttransplantation HCV recurrence across the spectrum of genotypes?